ArticleJournal of diabetes science and technology2025
Cost-Effectiveness Analysis of Real-Time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in People With Type 2 Diabetes Treated With Non-Intensive Insulin Therapy in South Korea.
Article in Journal of diabetes science and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nationwide Survey of Korean Endocrinologists on Barriers to Implementing Smart Healthcare Technologies.Endocrinology and metabolism (Seoul, Korea) · 2026Article
- Continuous Glucose Monitoring in Non-ICU Hospitalized Adults with Type 2 Diabetes: A Systematic Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThere is limited evidence regarding the cost-effectiveness of real-time continuous glucose monitoring (rt-CGM) in the management of type 2 diabetes in patients receiving basal insulin regimens in South Korea. This study aimed to address this gap by analyzing the cost-effectiveness of rt-CGM when compared with self-monitoring of blood glucose. RESEARCH DESIGN AND
methodsThe cost-effectiveness of rt-CGM was modeled using the IQVIA Core Diabetes Model from a South Korean payer perspective in a simulated cohort based on the Korea National Health and Nutrition Examination Survey. A remaining lifetime horizon (up to 50 years), and a discount rate of 4.5%
resultsThe use of rt-CGM resulted in an increase in quality-adjusted life expectancy of 0.490 QALYs and a KRW 13.3 million increase in costs compared with self-monitoring of blood glucose. The incremental cost-utility ratio in the base case analysis was KRW 27.1 million per QALY, below the willingness-to-pay threshold of KRW 47 million.
conclusionsrt-CGM is likely to be cost-effective versus self-monitoring of blood glucose in the management of patients with type 2 diabetes receiving basal insulin regimens in South Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.